Clinical Trials Search

Department: Neurology
Diagnosis: Neurology
Principal Investigator: Pamula MD, John
Sub-Investigator(s):
Sponsor: Duke
Details (Identifier #): NCT02478177
Title: Management of Acute Stroke Patients on Treatment with New Oral Anticoagulants: Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry"
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: AbbVie
Details (Identifier #): NCT02819635
Title: AbbVie M14-234, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: AbbVie
Details (Identifier #): NCT03006068
Title: M14-533, A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis (UC)
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
  • Morelli PA-C, Catherine
  • O'Neil PA-C, Kelby
  • Perry-Keaty, Cynthia
  • Schecter FNP, Jennifer
  • Srivatana MD, Panit
Sponsor: Roche
Details (Identifier #): NCT02624986
Title: BH29812, A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with idasanutlin in patients with relapsed or refractory follicular lymphoma and obinutuzumab or rituximab in combination with idasanutlin in patients with relapsed or refractory diffuse large B-cell lymphoma
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
  • Morelli PA-C, Catherine
  • O'Neil PA-C, Kelby
  • Perry-Keaty, Cynthia
  • Schecter FNP, Jennifer
  • Srivatana MD, Panit
Sponsor: Roche
Details (Identifier #): NCT03135262
Title: BH39147, A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Idasanutlin and Venetoclax in Patients with Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination with Idasanutlin and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma